Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in Parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro

Clinical Neuropharmacology

Volumn 28, Issue 4, 2005, Pages 155-160

  Miyazaki, Ikuko ^a   Asanuma, Masato ^a   Diaz Corrales, Francisco J ^a   Miyoshi, Ko ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dopamine quinone; Levodopa; Parkinson disease; Pergolide; Quinoprotein

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; PERGOLIDE; PROTEIN; QUINONE DERIVATIVE; QUINOPROTEIN; SEMIQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; ELECTRON SPIN RESONANCE; MOUSE; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGONISTS; ELECTRON SPIN RESONANCE SPECTROSCOPY; FUNCTIONAL LATERALITY; LEVODOPA; MICE; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PERGOLIDE; PROTEIN BINDING; QUINONES; SYMPATHOLYTICS;

EID: 23644452346     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000175523.33334.24     Document Type: Article

References (47)

1. Ahlskog JE, Muenter MD, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
2. Ogawa N. Factors affecting levodopa effects in Parkinson's disease. Acta Med Okayama. 2000;54:95-101.
3. Basma AN, Morris EJ, Nicklas WJ, et al. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem. 1995;64:825-832.
4. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA. 1996;93:1956-1961.
5. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PCl2 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest. 1995;95:2458-2464.
6. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-dopa-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res. 2003;5:165-176.
7. Asanuma M, Miyazaki I, Diaz-Corrales FJ, et al. Quinone formation as dopaminergic neuron-specific oxidative stress in pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama. 2004;58:221-233.
8. Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-dopa) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002;23:57-63.
9. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol. 1993;60:242-250.
10. Datla KP, Blunt SB, Dexter DT. Chronic L-dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord. 2001;16:424-434.
11. Ferrario JE, Delfino MA, Stefano AV, et al. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res. 2003;47:431-436.
12. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem. 1993;61:1470-1478.
13. Mytilineou C, Walker RH, JnoBaptiste R, et al. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther. 2003;304:792-800.
14. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2000;1:181-195.
15. Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA. 2000;97:11869-11874.
16. Fornstedt B, Rosengren E, Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology. 1986;25:451-454.
17. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978;14:633-643.
18. Haque ME, Asanuma M, Higashi Y, et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta. 2003;1619:39-52.
19. Haque ME, Asanuma M, Higashi Y, et al. Overexpression of Cu-Zn superoxide dismutase protects neuroblastoma cells against dopamine cytotoxicity accompanied by increase in their glutathione level. Neurosci Res. 2003;47:31-37.
20. Kuhn DM, Arthur RE Jr, Thomas DM, et al. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem. 1999;73:1309-1317.
21. Lai CT, Yu PH. Dopamine- and L-b-3,4-dihydroxyphenylalanine hydrochloride (L-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and anti-oxidative factors. Biochem Pharmacol. 1997;53:363-372.
22. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19:1484-1491.
23. Offen D, Ziv I, Sternin H, et al. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol. 1996;141:32-39.
24. Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol. 1986;45:551-553.
25. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-47.
26. Asanuma M, Ogawa N, Nishibayashi S, et al. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn Ther. 1995;329:221-230.
27. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, et al. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 1998;790:202-208.
28. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem. 1996;67:2208-2211.
29. Chalimoniuk M, Stepien A, Strosznajder JB. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-dopa enhances serum antioxidant enzyme activity in Parkinson disease. Clin Neuropharmacol. 2004;27:223-229.
30. Liu WG, Chen Y, Li B, et al. Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells. Neurochem Res. 2004;29:2207-2214.
31. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology. 1985;35:291-295.
32. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 1985;35:296-299.
33. Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson disease with pergolide. Neurology. 1981;31:675-682.
34. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 1995;45:S13-S21.
35. Sage JI, Duvoisin RC. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 1985;8:260-265.
36. Kaneko S, Hikida T, Watanabe D, et al. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science. 2000;289:633-637.
37. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997.
38. Paz MA, Fluckiger R, Boak A, et al. Specific detection of quinoproteins by redox-cycling staining. J Biol Chem. 1991;266:689-692.
39. Borg DC. Transient free radical forms of hormones: Epr spectra from catecholamines and adrenochrome. Proc Natl Acad Sci USA. 1965;53:633-639.
40. Korytowski W, Sarna T, Kalyanaraman B, et al. Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta. 1987;924:383-392.
41. Clement MV, Long LH, Ramalingam J, et al. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem. 2002;81:414-421.
42. Choi HJ, Lee SY, Cho Y, et al. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem Int. 2005;46:329-335.
43. Dethy S, Laute MA, Luxen A, et al. Effect of pergolide on endogenous and exogenous L-dopa metabolism in the rat striatum: a microdialysis study. J Neural Transm Gen Sect. 1995;101:1-11.
44. Foppoli C, Coccia R, Cini C, et al. Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta. 1997;1334:200-206.
45. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem. 1995;64:919-924.
46. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem. 1976;19:37-40.
47. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976;72:248-254.